A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug. The studies presented a number of critical challenges to the PRA project team. Through teamwork and strategic planning, PRA developed plans that helped us reach the client’s milestones and resulted in successful site activations and first patient in.
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.
PRA Leads Novel Multiple Myeloma Drug Development
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract…
Awards and Recognition
PRA and our employees have won numerous awards and accolades in the CRO industry. In 2019, we were named PharmaTimes’ Clinical Company of the…